- Home
- LTC vs MNKD Comparison
LTC vs MNKD Comparison
Compare LTC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LTC | MNKD |
|---|---|---|
| Founded | 1992 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 2004 |
Fundamental Metrics
Financial Performance| Metric | LTC | MNKD |
|---|---|---|
| Price | $38.38 | $2.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $39.00 | $8.64 |
| AVG Volume (30 Days) | 337.3K | ★ 6.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | ★ 23.53 | N/A |
| EPS | ★ 2.52 | 0.02 |
| Revenue | $262,854,000.00 | ★ $348,966,000.00 |
| Revenue This Year | N/A | $33.40 |
| Revenue Next Year | $13.24 | $16.48 |
| P/E Ratio | ★ $15.35 | $130.25 |
| Revenue Growth | ★ 25.26 | 22.23 |
| 52 Week Low | $31.70 | $2.52 |
| 52 Week High | $40.80 | $6.51 |
Technical Indicators
Market Signals| Indicator | LTC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 45.78 | 20.81 |
| Support Level | $34.13 | N/A |
| Resistance Level | $40.05 | $6.18 |
| Average True Range (ATR) | 0.71 | 0.15 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 22.64 | 0.67 |
Price Performance
Historical ComparisonAbout LTC LTC Properties Inc.
LTC Properties Inc is a real estate investment trust. It invests in seniors housing and health care properties, mainly through ownership, sale-leasebacks, mortgage financing, joint ventures, construction financing, and structured finance solutions, including preferred equity, bridge, and mezzanine lending. The company's investment portfolio comprises several properties located throughout the USA, the majority of which are seniors housing and skilled nursing properties. The firm conducts and manages its business as two operating segments: Real Estate Investments, which generates maximum revenue, and SHOP.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.